Kinarus-Logo_RGB.jpg
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
06 déc. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report...
Kinarus-Logo_RGB.jpg
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
22 nov. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Method-of-use-patent covers KIN001 in ophthalmic diseasesFurther strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
16 nov. 2022 01h00 HE | Kinarus Therapeutic Holding AG
Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunitiesMultiple opportunities for KIN001 in indications with high unmet need are...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Provides Strategic Update
04 nov. 2022 02h00 HE | Kinarus Therapeutic Holding AG
Exploring financial and strategic options to fund Phase 2 trials of KIN001 in wet age-related macular degeneration and idiopathic pulmonary fibrosisKINFAST phase 2 clinical trial of KIN001 in mild to...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
30 sept. 2022 01h00 HE | Kinarus Therapeutic Holding AG
KINETIC, a Phase 2 clinical study of KIN001, an oral drug combination, to be discontinued following recommendation of the DSMBKIN001 was shown to be safe and well toleratedEnrollment in the Phase 2...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics Reports H1 2022 Financial Results and Provides Corporate Update
31 août 2022 01h00 HE | Kinarus Therapeutic Holding AG
Interim data from Phase 2 KINETIC clinical trial of KIN001 to treat hospitalized COVID-19 patients expected in Q3 2022First patient dosed with in Phase 2 KINFAST clinical trial with ambulatory...
Kinarus-Logo_RGB.jpg
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
29 août 2022 01h00 HE | Kinarus Therapeutic Holding AG
KINFAST to evaluate ability of KIN001 to reduce severity and duration of symptoms in ambulatory COVID-19 patientsInterim data from ongoing Phase 2 KINETIC trial in hospitalized Covid-19 patients...
Kinarus Therapeutics to hold webinar on a new approach to treating COVID-19
22 août 2022 01h05 HE | Kinarus Therapeutic Holding AG
KIN001 has synergistic antiviral, anti-inflammatory activity, and anti-fibrotic mechanismsPhase 2 trials of KIN001 in hospitalized and ambulatory COVID-19 patients ongoingInterim data from Phase 2...
Kinarus announces the issuance of convertible notes of up to CHF 20 million to an entity managed by Yorkville
22 août 2022 01h00 HE | Kinarus Therapeutic Holding AG
Financing to be drawn in tranchesFinancing will enable Kinarus to advance the clinical development of KIN001 Basel, Switzerland, August 22, 2022. Kinarus Therapeutics Holding AG (SIX: KNRS)...